Savolitinib vs. Sunitinib in MET-driven PRCC.

NCT03091192 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma
Carcinoma, Renal Cell
Kidney Neoplasms
Urologic Neoplasms
Kidney Diseases
Neoplasms by Site
Enzyme Inhibitors
Protein Kinase Inhibitors

Interventions

DRUG: Savolitinib
DRUG: Sunitinib

Sponsor

AstraZeneca

Collaborators

[object Object]